Dr. Joshua Reynolds is the Founder and CEO of Atlas Biotech, a startup launched in May 2024 in State College, Pennsylvania. Atlas Biotech focuses on accelerating and derisking the preclinical drug development process, particularly in oncology. The company collaborates with academic labs and pharmaceutical companies to predict potential drug resistance pathways through mutational mapping, helping prioritize drug candidates for clinical trials. Their National Cancer Institute (NCI)-funded project, quantitative deep mutational scanning, offers unique insights into the acquisition and evolution of drug resistance, aiming to streamline drug discovery and bring more durable cancer therapies to patients faster.

Josh has been awarded multiple translational grants funded by the National Institutes of Health (NIH) and the National Science Foundation (NSF). Throughout his research career, he has conducted studies on pharmacogenetics, genetic profiling, and anticancer drug development. These experiences have provided him with expertise in structural oncology, translational pharmacology, and the biopharmaceutical ecosystem.